ERBB2 and neoplasm: Although Herceptin has been shown to be effective in inhibiting tumor growth in a limited population of HER2-postive metastatic breast cancer patients, elicitation of an active and more comprehensive immune response that includes both antibody and T-cell responses may provide more effective protection [27].